You can't use Pembro in animal studies, but we did a study in melanoma using the mouse equivalent and it showed quite a bit of promise. The problem with immuno therapy combo trials is it is hard to know if they will work until Phase 3. You just have to look at IMM to see this effect in action - IMM should have a market cap far higher than it does, but the market is sceptical because there have been so many promising immune combinations in Phase 1 & 2 that looked fantastic that failed in Phase 3.
Our approach at RAC is to minimise clinical risk by pursuing opportunities that can be proven early in clinical development.
RAC Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)